TACR1 and breast cancer: first demonstrated that TRPV1+ PSNs do not affect the growth of primary mammary tumors but inhibit the formation of cardiac and pulmonary metastases, via a mechanism involving SP and its receptor neurokinin-1 receptor (NK-1R) (215, 216).